N-aminated Peptide Beta-Sheet Mimics Inhibit Amyloid-Beta Aggregation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Alzheimer's disease do not effectively slow disease progression or provide a cure, highlighting the need for new therapies that can inhibit amyloid-beta aggregation.
Innovation Solution
Development of short N-aminated peptides, including mono-, di-, and tri-aminated peptides, which are administered to reduce or inhibit amyloid-beta aggregation, thereby treating Alzheimer's disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current Alzheimer's disease treatments are used, then symptom relief is provided, but disease progression cannot be slowed or cured
Solution Approach 1:
The patent modifies the chemical structure of peptide compounds by introducing N-amination at specific positions to create beta-sheet mimics. This structural parameter change enables the compounds to specifically bind to and inhibit amyloid-beta aggregation, addressing the limitation of current treatments that cannot slow disease progression.
Solution Approach 2:
The invention combines beta-sheet mimetic structures with amyloid-beta binding capability to create composite therapeutic compounds. These compounds integrate multiple functional elements: the beta-sheet mimicry domain for structural recognition and the binding domain for specific interaction with amyloid-beta, achieving both symptom relief and progression control.
2Productivity
If amyloid-beta aggregation is targeted for inhibition, then disease progression can be slowed, but new therapeutic mechanisms are required
Solution Approach 1:
The patent employs small molecule compounds as intermediaries that mediate between the therapeutic goal (inhibiting amyloid-beta aggregation) and the molecular target (amyloid-beta peptides). These compounds act as molecular mediators that bind to amyloid-beta and prevent aggregation without requiring complex biological systems or multiple components.
Solution Approach 2:
The invention replaces complex biological mechanisms (such as enzyme-based therapies or gene therapy) with a simpler chemical mechanism. The small molecule compounds use direct chemical binding and structural mimicry to inhibit aggregation, substituting complex biological systems with a more tractable chemical approach.
3Manufacturing precision
If peptide compounds are designed to mimic beta-sheets, then amyloid-beta binding is enhanced, but synthesis complexity increases
Solution Approach 1:
The patent divides the peptide compound into distinct functional segments: the N-aminated beta-sheet mimetic core structure and additional amino acid residues. This segmentation allows for modular synthesis where the core mimetic structure can be prepared separately and then combined with other residues, reducing overall synthesis complexity while maintaining binding specificity.
Solution Approach 2:
The invention introduces N-amination at specific local positions within the peptide structure rather than uniformly modifying all residues. This localized modification approach concentrates the structural changes needed for beta-sheet mimicry at key positions, achieving high binding specificity while minimizing the overall complexity of synthesis compared to global modification strategies.
Data Source
AI summary
Disclosed herein are compounds comprising short N-aminated peptides and compositions comprising the same. The disclosed compounds and compositions maybe used in methods of inhibiting amyloid-beta aggregation and treating Alzheimer's disease.